Datamonitor''s Strategic Perspectives 2002: Cancer Innovatives Part I (Immunotherapies) provides a comprehensive description and commercial analysis of novel immunotherapies, including cytokines, monoclonal antibodies and vaccines, launched in 2001 and in the late-stage pipeline with potential approval by 2008. The report includes: * Overview of the currently targeted and remaining potentially attractive indications for cancer immunotherapies R&D * Historical analysis of the cancer immunotherapies market, broken down by leading players and by country-specific contribution to the overall market • Competitive positioning and insightful analysis of future leading players in the cancer immunotherapies market, by product and by drug class * Epidemiology- and market forces-based predictions for immunotherapies subclass competition and growth. • Sales forecasts for the cancer immunotherapies market as a whole, by individual drug classes, and by leading drugs, through 2008
